China NMPA Product Recall - Sample diluent

Roche Diagnostics Products (Shanghai) Co., Ltd. initiated a voluntary Level III recall for specific batches of its sample diluent, as reported by the National Medical Products Administration (NMPA) on December 10, 2020. This recall, also publicized by the Shanghai Municipal Drug Administration, was a direct result of internal investigations by Roche Diagnostics. The primary issue discovered was a significant discrepancy in the packaging specifications presented on the Chinese and English labels for certain product batches. Such inconsistencies can lead to confusion regarding product usage or contents. The affected sample diluent batches are associated with Registration Certificate Nos. 20171131 and 20171113. Although the document does not specify particular inspection dates, the proactive nature of Roche's internal investigation led to this public disclosure and subsequent recall on December 10, 2020. Under the regulatory oversight of the NMPA, the company is mandated to remove all identified non-compliant products from distribution. This action highlights the stringent regulatory framework governing medical devices in China, emphasizing the critical need for accurate, consistent, and compliant product labeling to ensure patient safety and proper medical use. The Level III classification indicates that the issue is unlikely to cause adverse health consequences but requires corrective action to maintain quality standards.